SCHEMBL2384477

SCHEMBL2384477

COC(=O)[C@H](Cc1ccccc1)N(N[C@@H](Cc1ccccc1C)C(=O)O)C(=O)OC(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGA4 P13612 2/20 0.44
ITGB7 P26010 2/20 0.44
ALDH1A1 P00352 2/20 0.41
JAK2 O60674 1/20 0.41
S1PR4 O95977 1/20 0.41
LMNA P02545 1/20 0.41
HSP90AA1 P07900 1/20 0.41
THRB P10828 1/20 0.41
HPGD P15428 1/20 0.41
XBP1 P17861 1/20 0.41
HTT P42858 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
ACE P12821 1/20 0.40
KLK5 Q9Y337 2/20 0.40
OPRK1 P41145 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
AKT1 P31749 1/20 0.37
CTSS P25774 2/20 0.37
GAA P10253 1/20 0.37
CTSL P07711 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2386629 0.93 ITGA4 (0.41) ITGA4ITGB7ALDH1A1JAK2S1PR4
SCHEMBL2904541 0.93 JAK2 (0.42) ITGA4ITGB7ALDH1A1JAK2S1PR4
SCHEMBL2385485 0.92 ITGA4 (0.49) ITGA4ITGB7ALDH1A1LMNATHRB
SCHEMBL2386839 0.91 ITGA4 (0.47) ITGA4ITGB7ALDH1A1ACEKLK5
SCHEMBL2384488 0.90 ITGA4 (0.42) ITGA4ITGB7ALDH1A1LMNAACE
SCHEMBL2386586 0.89 ITGA4 (0.56) ITGA4ITGB7ALDH1A1ACEKLK5
SCHEMBL2388080 0.89 ABCB1 (0.42) ALDH1A1OPRK1L3MBTL1GAACTSL
SCHEMBL2388324 0.89 ATM (0.47) ITGA4ITGB7ACEKLK5L3MBTL1
SCHEMBL2386578 0.88 ITGA4 (0.43) ITGA4ITGB7ALDH1A1THRBACE
SCHEMBL2387144 0.87 ITGA4 (0.42) ITGA4ITGB7ACEKLK5PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8017378-B2 Method for production of optically active biphenylalanine compound or salt or ester thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-09-13 US disclosed
EP-1980622-B1 METHOD FOR PRODUCTION OF AN OPTICALLY ACTIVE BIPHENYLALANINE COMPOUND OR SALT OR ESTER THEREOF SUMITOMO CHEMICAL CO (JP) 2010-08-18 EP disclosed
US-20090011475-A1 Method For Production of Optically Active Biphenylalanine Compound or Salt or Ester Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-01-08 US disclosed
EP-1980622-A1 METHOD FOR PRODUCTION OF OPTICALLY ACTIVE BIPHENYLALANINE COMPOUND OR SALT OR ESTER THEREOF Sumitomo Chemical Company, Limited (JP) 2008-10-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090011475-A1 Method For Production of Optically Active Biphenylalanine Compound or Salt or Ester Thereof DNPEP, APEH, PAH ITGA4 4819/4885ITGB7 4625/4885ALDH1A1 755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.